|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Healthcare Company News 
VentriPoint Diagnostics Ltd. Ventripoint Diagnostics Announces Initial Closing of Current Offering and Submission for Regulatory Approval
VentriPoint Diagnostics Ltd. Ventripoint Diagnostics Announces Initial Closing of Current Offering and Submission for Regulatory Approval
Ventripoint Diagnostics Announces Initial Closing of Current Offering and Submission for Regulatory Approval
Tuesday, 10 March 2009 06:53 | 
| Company News - VentriPoint Diagnostics Ltd. |
VentriPoint Diagnostics Ltd. announced the initial closing of its secured debenture offering (the “Offering”) and the submission of the comprehensive Technical File by its wholly owned subsidiary, VentriPoint, Inc. (“VentriPoint”) in its efforts to receive CE marking to permit the marketing of its VentriPoint Medical System (“VMS”) in Europe.
The VMS provides key measurements and accurate 3-D reconstructions of the right ventricle of a patient’s heart from standard two-dimensional ultrasound images.
Joe Ashley, President & CEO of the Corporation, explained, “With the very difficult financing environment in which we have found ourselves, we are extremely pleased and grateful to those investors who have recognized the importance of our solution to patients with heart disease and are supporting our efforts as we transition into the exciting commercialization phase of our growth. The net proceeds of the initial closing of $236,000 will provide operational capital to pursue regulatory approvals and to commence implementation of our commercialization plans that will bring the VMS heart diagnostic and monitoring tool to market. Another closing of the Offering is being scheduled.”
VentriPoint has engaged Intertek Semko AB as its Notified Body to conduct the third‐party conformity assessment procedures as required by the Medical Device Directive recognized by the 30 member states of the European Economic Area. Pursuant with this engagement, VentriPoint has submitted its comprehensive Technical File which incorporates its previously announced ISO 13485:2003 certification. A positive conclusive review by Intertek Semko AB will provide VentriPoint with a CE‐mark to permit the marketing and selling of the VentriPoint Medical System within select European Countries.
About VentriPoint Diagnostics Ltd.
VentriPoint creates diagnostic tools to monitor patients with heart disease – the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Medical System (“VMS”) generates critical heart measurements in a rapid and inexpensive manner not currently available. Health Canada has granted licensed approval for the VMS breakthrough diagnostic tool which is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The VMS, together with its associated online service, is being expanded to cover a variety of heart related disease states, including congenital heart disease and pulmonary hypertension.
Source: VentriPoint Diagnostics Ltd.
Joe Ashley, President & CEO of the Corporation, explained, “With the very difficult financing environment in which we have found ourselves, we are extremely pleased and grateful to those investors who have recognized the importance of our solution to patients with heart disease and are supporting our efforts as we transition into the exciting commercialization phase of our growth. The net proceeds of the initial closing of $236,000 will provide operational capital to pursue regulatory approvals and to commence implementation of our commercialization plans that will bring the VMS heart diagnostic and monitoring tool to market. Another closing of the Offering is being scheduled.”
VentriPoint has engaged Intertek Semko AB as its Notified Body to conduct the third‐party conformity assessment procedures as required by the Medical Device Directive recognized by the 30 member states of the European Economic Area. Pursuant with this engagement, VentriPoint has submitted its comprehensive Technical File which incorporates its previously announced ISO 13485:2003 certification. A positive conclusive review by Intertek Semko AB will provide VentriPoint with a CE‐mark to permit the marketing and selling of the VentriPoint Medical System within select European Countries.
About VentriPoint Diagnostics Ltd.
VentriPoint creates diagnostic tools to monitor patients with heart disease – the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Medical System (“VMS”) generates critical heart measurements in a rapid and inexpensive manner not currently available. Health Canada has granted licensed approval for the VMS breakthrough diagnostic tool which is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The VMS, together with its associated online service, is being expanded to cover a variety of heart related disease states, including congenital heart disease and pulmonary hypertension.
Source: VentriPoint Diagnostics Ltd.
